Clinical trials: Cancer Disease Progression
Urothelial Carcinoma
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and…
- Trial name
- NCT07043972
- Testing
- Gemcitabine, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Fox Chase Cancer Center
Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction…
- Trial name
- NCT06415669
- Testing
- Paclitaxel for injection (albumin-bound), Adebrelimab, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Chronic Lymphocytic Leukemia
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00275054
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- 91 sites in Austria, France and 1 more
- Volunteers
- 825 people
- Sponsor
- German CLL Study Group
Cholangiocarcinoma, Gallbladder Cancer
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line…
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- BOLSTER (NCT05712356)
- Testing
- certepetide, Durvalumab, Cisplatin
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- Lisata Therapeutics, Inc.
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT07218692
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Sponsor
- City of Hope Medical Center
Rectal Neoplasms
"Wait-and-see" Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer
The aim of this prospective observational cohort study is to provide short and long term oncological and functional outcome data on organ preserving treatment in good responders after a standard indication for neoadjuvant…
- Trial name
- NCT03426397
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 220 people
- Sponsor
- The Netherlands Cancer Institute
Multiple Myeloma
Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
A number of strategies have been proposed to improve the outcome of ASCT. The three main strategies are to incorporate novel agents into the induction regimen, using maintenance therapy following ASCT and the final strategy is to…
- Trial name
- BuMelMCRN001 (NCT01702831)
- Testing
- Busulfan, Melphalan, Lenalidomide
- Where
- 10 sites in Canada
- Volunteers
- 78 people
- Sponsor
- University Health Network, Toronto
Non-Small-Cell Lung Cancer
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
- Trial name
- NCT04681131
- Testing
- CAB-AXL-ADC, PD-1 inhibitor
- Where
- 60 sites in United States, Greece and 5 more
- Volunteers
- 85 people
- Sponsor
- BioAtla, Inc.
Gastroenteropancreatic Neuroendocrine Tumor
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive…
- Trial name
- SAUNA (NCT05701241)
- Testing
- Somatostatin analog
- Where
- 19 sites in Belgium, Netherlands
- Volunteers
- 270 people
- Sponsor
- University Hospital, Antwerp
EGFR Gene Mutation, Lung Cancer
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
- Conditions
- EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic
- Trial name
- NCT03755102
- Testing
- Dacomitinib, Osimertinib
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Prostate
A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
The primary objective was to evaluate the PSA (biochemical) progression-free survival (PFS) of high-risk metastasis-free PC patients, treated with LH-RH agonist for one year with or without docetaxel after prior radical…
- Trial name
- RisingPSA (NCT00764166)
- Testing
- Docetaxel + hormonal treatment (LH-RH agonist), Hormonal treatment (LH-RH agonist)
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovarian Cancer
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
The primary objective of this extension protocol is to evaluate the early safety of a new schedule of NGR-hTNF given weekly, instead of every 3 or 4 weeks, in a cohort of 12 patients randomized to the experimental arm A, as…
- Trial name
- NCT03804866
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 4 sites in Italy
- Volunteers
- 14 people
- Sponsor
- AGC Biologics S.p.A.
Solid Tumor
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
AB-106 will be administered once a day. Each treatment cycle is defined as 21 days of continuous medication. Dosing will continue until any of the following conditions are met: disease progression, intolerable drug-related…
- Trial name
- NCT04617054
- Testing
- AB-106
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Nuvation Bio Inc.
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT02099864
- Testing
- Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- OHSU Knight Cancer Institute
Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse
The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin…
- Trial name
- NCT00498667
- Where
- Israel
- Sponsor
- Rambam Health Care Campus
Metastatic Breast Cancer
Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients
The purpose of the study is to evaluate the impact of an immunotherapy by IL-7 on CD4 lymphopenia, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients.
- Trial name
- NCT01368107
- Testing
- interleukin 7
- Where
- 3 sites in France
- Volunteers
- 24 people
- Sponsor
- Centre Leon Berard
Progression
A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
- Trial name
- NCT04905056
- Testing
- Ablation therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Breast Cancer
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression
This is an open-label, single arm, multicenter phase II study evaluating treatment with pembrolizumab in combination with paclitaxel in patients with locally advanced or metastatic non-luminal hormone receptor-positive (HR+)…
- Trial name
- TATEN (NCT04251169)
- Testing
- Pembrolizumab, Paclitaxel
- Where
- 7 sites in Spain
- Volunteers
- 20 people
- Sponsor
- SOLTI Breast Cancer Research Group
Prostate Cancer, Metastatic Prostate Cancer
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
This study is designed to test the hypothesis that using Sipuleucel-T (Provenge) in combination with new hormonal agents (NHA) (abiraterone, enzalutamide, apalutamide) for the treatment of participants with asymptomatic…
- Trial name
- NCT05751941
- Testing
- Abiraterone, Enzalutamide, Apalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca